ERBB2 and neoplasm: It turns out that in many cases of patients treated with therapeutic antibodies, similar to what was described above for patients carrying HER2+ tumors and treated with anti-HER2 antibodies, patients eventually relapse or develop progressive disease [100], suggesting that tumors either possess or acquire intrinsic resistance mechanisms, allowing tumor escape [100,101,102].